New Blood DNA Test Detects Early Gastric Cancer
A novel red blood cell DNA profiling method achieves high sensitivity in identifying early-stage stomach cancer.
Updated on Oct. 20, 2026 in Cancer
Live Poll
Do you trust new non-invasive blood tests to reliably detect early-stage cancers?
Researchers published a 2026 study in the journal Med detailing a new DNA profiling method for gastric cancer detection. Using shallow whole-genome sequencing of red blood cells, the approach identifies early-stage disease with high sensitivity.
Why it matters
Detecting gastric cancer is often difficult due to the invasive nature of endoscopy and the limited sensitivity of current biomarkers. This new method offers a non-invasive alternative that could improve diagnostic accuracy for high-risk patients.
The study of 865 individuals, including 434 gastric cancer patients and 431 controls, used 1-2 mL of peripheral blood to identify 1,000 read-depth features. The classifier achieved a 95% area under the receiver operating characteristic curve in test cohorts.
The players
Med
Med is a peer-reviewed medical journal that publishes high-impact research across various clinical and biomedical sciences.
The details
The diagnostic technique relies on shallow whole-genome sequencing of rbcDNA to isolate features associated with malignancy. By utilizing machine learning, the model identified 80% of gastric cancer cases that previously tested negative for standard tumor markers.
Timeline
The study results were published in the journal Med in 2026.
The Big Picture
This research expands the liquid biopsy diagnostic paradigm by applying red blood cell DNA sequencing to gastric cancer. It marks a shift from relying on traditional tumor markers toward analyzing the genomic characteristics of blood cells for early detection.
Patients may eventually benefit from a non-invasive diagnostic option that avoids the discomfort of endoscopy for routine screening. The technology could significantly increase early detection rates, potentially allowing for earlier medical intervention.
The takeaway
This method highlights the potential for blood-based genomic profiling to overcome limitations in current cancer screening. Future diagnostic efforts will likely focus on how such technologies can be standardized for widespread clinical implementation.
Further reading
For more information on diagnostic advancements, visit the Cancer section.
Live Poll
Do you trust new non-invasive blood tests to reliably detect early-stage cancers?
